MedTrace Logo

Efficacy Of Zinc Towards The Outcome on Children With Sepsis

NCT06556511 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2024-08-16

No results posted yet for this study

Summary

Sepsis is a life-threatening organ failure induced by a compromised immune response to infection. Sepsis is a leading cause of morbidity and mortality (50-60%) in children treated in inpatient and critical care units. Children suffering from immunodeficiency have a higher mortality rate. Several studies in recent years have revealed that zinc homeostasis may be a significant role in the prevention of sepsis. It was important to conduct this study to determine the efficacy of zinc in children suffering from sepsis.

Conditions

Interventions

DRUG

Zinc Sulfate

Zinc is administered at a dose of 10 mg per day for children under the age of 6 months, and 20 mg per day for children above the age of 6 months accompanied with standard therapy in the zinc group for a period of 10 days.

DRUG

Placebo

Placebo is administered with standard therapy in the placebo group for a period of 10 days.

Sponsors & Collaborators

  • Hasanuddin University

    collaborator OTHER

  • dr. Aldora Jesslyn Oentari

    lead OTHER

Principal Investigators

  • Aldora Jesslyn Oentari · Hasanuddin University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Month
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-01
Primary Completion
2024-05-31
Completion
2024-05-31

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06556511 on ClinicalTrials.gov